Pulse Biosciences Dirección
Dirección controles de criterios 2/4
El CEO de Pulse Biosciences es Paul LaViolette , nombrado en Jan 2025, tiene una permanencia de 1.67 años. compensación anual total es $14.20M, compuesta por 5% salario y 95% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.022% de las acciones de la empresa, por valor de $773.22K. La antigüedad media del equipo directivo y de la junta directiva es de 2.9 años y 8.8 años, respectivamente.
Información clave
Paul LaViolette
Chief Executive Officer (CEO)
US$14.2m
Compensación total
| Porcentaje del salario del CEO | 4.99% |
| Permanencia del CEO | 1.7yrs |
| Participación del CEO | 0.02% |
| Permanencia media de la dirección | 2.9yrs |
| Promedio de permanencia en la Junta Directiva | 8.8yrs |
Actualizaciones recientes de la dirección
Recent updates
PLSE: Pivotal nsPFA Trials And Early Data Will Drive Bullish Outlook
Analysts have revised their fair value estimate for Pulse Biosciences to $58 from $35, citing growing confidence in the company's differentiated nanosecond pulse field ablation platform, positive early clinical signals, and the potential impact of ongoing pivotal studies and future partnerships. Analyst Commentary on Pulse Biosciences Recent Street research on Pulse Biosciences has taken a more constructive tone, with several bullish analysts highlighting the company’s nanosecond pulsed field ablation platform and early clinical data as key supports for their valuation work.
PLSE: Pivotal Nanosecond Ablation Data And Partnerships Will Shape 3b Market Access
Analysts have lifted the fair value estimate for Pulse Biosciences to $45.25 from $41, citing Street research that highlights its differentiated nanosecond pulsed field ablation platform, positive early clinical data, progress in pivotal studies, and what they view as improving success probabilities following recent updates. Analyst Commentary Recent Street research on Pulse Biosciences centers on the potential of its nanosecond pulsed field ablation platform, the pace of clinical development, and how these factors feed into valuation and execution risk for investors following the story into late 2026.PLSE: Clinical And Regulatory Progress Will Test Access To 3b Ablation Market
The analyst price target for Pulse Biosciences has been reset from about $30.67 to $41.00, with analysts pointing to improving success probabilities for its nanosecond pulsed field ablation platform and continued clinical and regulatory progress as key drivers of their updated views. Analyst Commentary Recent Street research on Pulse Biosciences highlights both optimism around the nanosecond pulsed field ablation platform and a focus on the execution risks that come with an early stage commercial story.
Slower Pulsed Field Ablation Adoption Will Limit Revenue Scale And Delay Profitability
Catalysts About Pulse Biosciences Pulse Biosciences develops medical devices based on nanosecond pulsed field ablation technology for cardiac and thyroid procedures. What are the underlying business or industry changes driving this perspective?PLSE: Cardiac Ablation Data And Index Inclusion Will Guide Fairly Valued Outlook
Analysts have lifted their price target on Pulse Biosciences to $35 from $30, citing preliminary support for the nsPFA platform's safety and efficacy profile in cardiac ablation and its potential to address a large electrophysiology market opportunity. Analyst Commentary on Pulse Biosciences Recent Street research on Pulse Biosciences points to growing confidence in the potential of its nanosecond pulsed field ablation, or nsPFA, platform in cardiac ablation.PLSE: Ablation Platform And Clinical Data Will Drive Access To 3b Market
Analysts have lifted the fair value estimate for Pulse Biosciences from about $22 to roughly $30.67 per share, citing the company’s differentiated nanosecond pulsed field ablation platform and the roughly $3 billion electrophysiologists ablation market opportunity as key drivers behind a Street price target of $32. Analyst Commentary Recent Street research on Pulse Biosciences centers on the potential of its nanosecond pulsed field ablation platform and how that might justify the latest fair value estimate and price targets around US$32 per share.PLSE: Nanosecond Cardiac Ablation Platform Will Pursue Expanding Electrophysiology Opportunity
Analysts raised their price target on Pulse Biosciences stock from $30 to $32, citing its differentiated nanosecond pulsed field cardiac ablation platform and the $3 billion electrophysiology ablation market, which they estimate is growing 10% to 15% annually, with potential for the company to capture a meaningful share. Analyst Commentary Bullish analysts covering Pulse Biosciences emphasize that the stock is now being valued around a clearly defined opportunity in cardiac ablation, supported by a specific US$32 price target.Early Thyroid And Cardiac Applications Will Establish A Powerful Medical Device Platform
Catalysts About Pulse Biosciences Pulse Biosciences develops and commercializes medical devices that use proprietary nanosecond pulse field ablation technology for soft tissue and cardiac applications. What are the underlying business or industry changes driving this perspective?Pulse Biosciences (NASDAQ:PLSE) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Here's Why We're Not At All Concerned With Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...We're Not Very Worried About Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Pulse...Pulse Biosciences Stock: Signs Of Life Following Q1 Update
Summary We recap Q1 developments from Pulse Biosciences, Inc. The FDA has cleared the company's percutaneous electrode system, while the surgical clamp device for cardiac indications is still in the preclinical trial phase. Pulse Biosciences is making progress in its commercialization strategy, but financial uncertainties may keep the stock under pressure. Read the full article on Seeking AlphaWe're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Pulse Biosciences...We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Pulse Biosciences (NASDAQ:PLSE) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$80m |
| Mar 31 2026 | n/a | n/a | -US$75m |
| Dec 31 2025 | US$14m | US$709k | -US$73m |
| Sep 30 2025 | n/a | n/a | -US$75m |
| Jun 30 2025 | n/a | n/a | -US$68m |
| Mar 31 2025 | n/a | n/a | -US$60m |
| Dec 31 2024 | US$3m | n/a | -US$54m |
Compensación vs. Mercado: La compensación total de Paul($USD14.20M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD6.99M).
Compensación vs. Ingresos: La compensación de Paul ha aumentado mientras la empresa no es rentable.
CEO
Paul LaViolette (68 yo)
Mr. Paul Arthur LaViolette, M.B.A. is Member of Advisory Board of Carvolix SA from April 2026. He is Director of Vibrato Medical, Inc. Mr. LaViolette is President, Chief Executive Officer, at Pulse Bioscie...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 1.7yrs | US$14.20m | 0.022% $ 773.2k | |
| Chief Financial Officer | 1.6yrs | US$2.88m | 0.0022% $ 75.9k | |
| CTO & Director | 4yrs | US$869.89k | 0.40% $ 13.9m | |
| Chief Operating Officer | less than a year | sin datos | 0.0057% $ 199.7k | |
| VP of Accounting | 1.2yrs | sin datos | sin datos | |
| General Counsel & Corporate Secretary | 5.3yrs | sin datos | sin datos | |
| Vice President of Human Resources | 6.5yrs | sin datos | sin datos | |
| Senior Vice President of Engineering | 5yrs | sin datos | sin datos | |
| Chief Medical Officer | 3.3yrs | sin datos | sin datos | |
| Chief Science Officer of Cardiac Surgery | 2.9yrs | sin datos | sin datos | |
| Chief Medical Officer | 1.9yrs | sin datos | sin datos |
Equipo directivo experimentado: El equipo directivo de PLSE se considera experimentado (2.9 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 2.1yrs | US$14.20m | 0.022% $ 773.2k | |
| CTO & Director | 11yrs | US$869.89k | 0.40% $ 13.9m | |
| Independent Director | 6.1yrs | US$412.74k | 0% $ 0 | |
| Independent Co-Chairman | 8.8yrs | US$633.14k | 68.45% $ 2.4b | |
| Independent Director | less than a year | sin datos | sin datos | |
| Independent Director | 9.6yrs | US$704.61k | 1.22% $ 42.6m | |
| Lead Independent Director | 8.8yrs | US$631.80k | 0% $ 0 |
Junta con experiencia: La junta directiva de PLSE se considera experimentada (8.8 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/09 09:33 |
| Precio de las acciones al final del día | 2026/09/09 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Pulse Biosciences, Inc. está cubierta por 6 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| William Plovanic | Canaccord Genuity |
| Keith Hinton | Freedom Capital Markets |
| Anthony Petrone | Mizuho Securities USA LLC |